http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109172577-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate | 2018-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109172577-B |
| titleOfInvention | Application of burreed tuber component C in rhizoma sparganii in preparation of anti-blood stasis medicine |
| abstract | The invention disclosesAn application of a scirpusin component C in rhizoma sparganii in the synthesis of a medicament for resisting blood stasis is disclosed. The invention proves that the sparganiin C has obvious effect of resisting blood stasis for the first time, can be used for preparing the medicine for treating blood stasis, and proves that: the bursin C can obviously reduce the thromboxane B in the serum of a blood stasis model mouse 2 （Thromboxane B2，TXB 2 ) The levels of Fibrinogen (FIB), tissue Plasminogen Inhibitor-1 (PAI-1) and Endothelin (endo-1, ET-1) of a body can improve Thymus Index (TI), Spleen Index (SI) and liver index (HI) of mice, and the composition has higher clinical application value and development prospect in the aspect of treatment of blood stasis syndrome. |
| priorityDate | 2018-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.